01 1Taro Pharmaceutical Industries
01 1TIRBANIBULIN
01 1U.S.A
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2024-08-28
Pay. Date : 2024-07-23
DMF Number : 39837
Submission : 2024-08-01
Status : Active
Type : II
20
Taro Pharmaceutical Industries Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is TIRBANIBULIN, with a corresponding US DMF Number 39837.
Remarkably, this DMF maintains an Active status since its submission on August 01, 2024, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of August 28, 2024, and payment made on July 23, 2024, indicating their dedication to facilitating drug approvals, Categorized as Type II
